I. Opeida, M. Rudyk, V. Svyatetska, L. Skivka, O. Fedorchuk
; Taras Shevchenko National University of Kyiv, Kyiv, Ukraine,; Taras Shevchenko National University of Kyiv, Kyiv, Ukraine,; Taras Shevchenko National University of Kyiv, Kyiv, Ukraine,; Kavetsky Institute of Experimental pathology, onkology and radiobiology, NASU, Kyiv, Ukraine


The study of the responce of peripheral lymphoid structures to the presence of malignant tumor in the brain offers the challenge for the use of immunotherapeutic approaches for the treatment of this disease. This work was aimed to evaluate weight indices and cellularity of lymphoid organs in rat with C6 glioma. One was found that the growth of glioma is accompanied by changes in the cellularity of the organs of the lymphatic system. The observed changes indicate the likelihood of the presentation of C6 glioma antigens in peripheral lymphoid structures, as well as the negative impact of glioma growth on thymus and spleen homeostasis.


lymphoid organs; glioma; cellularity of the organ; mass index


Britta Engelhardt, Peter Vajkoczy& Roy OWeller. The movers and shapers in immune privilege of the CNS. Nature Immunology. 2017:18:123-131.

Alex F. deVos. Transfer of Central Nervous System Autoantigens and Presentation in Secondary Lymphoid Organs. JImmunol. 2002:169(10):5415-5423.

Mebius R.E., Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005:5(8):606-616.

McNeill K.A. Epidemiologyof Brain Tumors. Neurol Clin. 2016:34(4):981-998.

Trashkov A.P., Spirin A.L., Tsygan N.V. Glialnyeopyholigolovnogomozga:obshyeprinzupudiagnostykyandlechenya. Pediatr. 2015:4:75-84. Russian.

Meir E. G., Hadjipanayis C. G., Norden A. D. etal. Excitingnewadvancesinneuro-oncology: theavenuetoacureformalignant glioma. CA Cancer J. Clin. 2010:60:166-193.

Dunn-Pirio AM, Vlahovic G. Immunotherapy approaches in the treatment of malignant brain tumors. Cancer. 2017:123(5):734-750.

Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH. The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opin Drug Saf. 2017:16(3):277-287.

Barth R. F. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. NeuroOncology. 1998:96:91-102.

Grobben G., Deyn P., Slegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 2002:310:257-270.

KemerliC., TaskinM. M., SutpidelerN. etal. Histopathology, invasion, migration and tumorigenicity in the C6 rat glioma model. Turkish Neurosurgery. 2005:15(3):109-115.

Tumormodelsincancerresearch / Ed. B. Teicher. -N.-Y.: HumanaPress, 2011:693 p.

LouveauA, SmirnovI, KeyesTJ, EcclesJD, RouhaniSJ, PeskeJD, etal. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015:1:523-337.

Reznikov A. Problemy e'tiki pri provedenii e'ksperimental'nyh medicinskih i biologicheskih issledovanij na zhivotnyh. Vestn. NANUkrainy. 2001:1:5-7. Russian.

Kozlowska E., J. Kopec-Szlezak, N. Drela. Sensitivity of mouse lymphoid and nonlymphoid organsto. Silesian air pollutants. Ecotoxicol. Environ. Saf. 1997:37:10-16.

Pereduy V.G., Tkach S.M. Osnovyvnyntrysnyoymedyzyny / Pereduy V.G., Tkach S.M. . – Kyiv. Nova Knuga. 2010:1006. Ukranian.

Giovanni Tarantino, Antonella Scalera, Carmine Finelli. Liver-spleen axis: Intersection between immunity, infection sand metabolism. World. J. Gastroenterol. 2013:19(23): 3534-3542.

Maenhout S.K., Thielemans K., Aerts J.L. Location, location, location: functional and phenotypic heterogeneity between tumor-infiltratin gandnon-infiltratingmyeloid-derivedsuppressorcells. Oncoimmunology. 2014: 15; 3(10): e956579.

Pouliquen D.L. Hepatic mitochondrial function and brain tumours. Curr Opin Clin Nutr Metab Care. 2007:10(4):475-479.

Egner W.The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000:6:424-432.


  • There are currently no refbacks.